ArticleMycopathologia2026
Candidemia Attributed to a Urinary Tract Source: Retrospective Cohort Study of Risk Factors, Clinical Profiles, Therapeutic Approaches and Outcomes.
Article in Mycopathologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrinary-source candidemia is an uncommon but clinically relevant form of invasive candidiasis, often underrecognized and poorly characterized in the literature.
methodsRetrospective single-center study of adult patients with candidemia attributed to a urinary source between 2019 and 2023. Eligible cases were identified using predefined attribution criteria, requiring microbiologically confirmed Candida spp. bloodstream infection with significant candiduria by the same species, in the absence of an alternative clinically plausible source.
resultsAmong 526 positive blood cultures, 26 fulfilled the predefined criteria for urinary tract source attribution. The median age was 74 years. Most patients had a nephro-urological history, with frequent chronic kidney disease (15, 57.7%), obstructive uropathy (19, 73.1%), indwelling urinary devices (21, 80.8%) and recent urological procedures (19, 73.1%). Type 2 diabetes was present in 50% of patients (13), most receiving SGLT2 inhibitors. The majority presented with fever (23, 88.5%), and sepsis was frequent (14, 53.8%). Urinary symptoms were present in only half of the patients (14, 53.8%). Candida albicans was the most frequent isolate (13, 50%); followed by Candida glabrata (8, 30.8%) and Candida parapsilosis (5, 19.2%), both showing high rates of elevated fluconazole MICs. Empirical therapy was often discordant with final susceptibility. Combination antifungal therapy was used in 26.9% (7). Attributable mortality was 23.1% (6 deaths). Independent predictors of mortality included type 2 diabetes, Barthel Index < 50, therapeutic failure and septic shock.
conclusionsCandidemia with a presumed urinary tract source primarily affects frail patients with urological comorbidities, often presents with non-specific symptoms and is associated with significant morbidity and mortality. Combination antifungal therapy may be beneficial in selected cases. Early recognition and individualized management are essential to improve outcomes.
Indexed as
Identifiers
41860623What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.